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196Objective: Transapical aortic valve implantation is a recent therapeutic advance for aortic valvular disease. We
sought to identify complications—and the relevant technical and management considerations—from our learning
curve with this procedure.
Methods: We retrospectively reviewed perioperative complications during the first 60 transapical aortic valve
implantations at a single institution, performed under compassionate release for patients who were candidates
neither for conventional aortic valve replacement nor for transfemoral aortic valve implantation. Access was
through a small left anterolateral thoracotomy. Particular attention was paid to securing the apical access site.
Rapid ventricular pacing to reduce cardiac forward flow was used during balloon valvuloplasty and valve
deployment. Careful positioning was guided by echocardiography and fluoroscopy.
Results: This was a select, high-risk (mean Society of Thoracic Surgeons score, 12.3%  7.8% mortality)
cohort. Mean age was 81.1  7.8 years. Technical success was achieved in 59 (98.3%) cases. One valve was
malpositioned too far toward the ventricle, necessitating that a second device be implanted within it. In-hospital,
30-day mortality was 18.3% (11 deaths) overall, decreasing from 33.3% in the first 15 patients to 13.3% in the
subsequent 45 patients. The only intraoperative death probably resulted from left main ostial obstruction by ex-
tensively calcified aortic cusps. Significant left ventricular apical bleeding occurred in 3 (5.0%) patients. Other
complications included stroke in 2 (3.3%) patients and permanent atrioventricular block in 3 (5.0%). There were
4 (6.6%) cases of late pseudoaneurysm of the left ventricular apical access site.
Conclusions: Important lessons have been learned from our early experience with transapical aortic valve
implantation, and these may guide others as this technology is adopted more broadly. (J Thorac Cardiovasc
Surg 2010;140:196-202)Since the first implant by Cribier and associates,1 transcath-
eter aortic valve implantation ushered in a new era in the
surgical treatment of aortic stenosis.2 For high-risk patients
with multiple comorbidities, this technique can provide relief
of valvular stenosis,3 often with less morbidity than conven-
tional aortic valve replacement (AVR).
To date, transfemoral and transapical transcatheter aortic
valve implantation has only been offered in North America
to very high-risk patients on a compassionate basis4-8 or in
the context of a trial. Consequently, perioperative risks
remain high by virtue of patients’ comorbid conditions and
poor preoperative medical status. Because such patient
factors are immutable, mitigating the procedural risks
through good surgical technique becomes pivotal in tipping
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The Journal of Thoracic and Cardiovascular SurgWe9 have been performing transapical aortic valve
implantation (TAVI) since October 2005. As the technology
moves toward widespread availability, operators and
patients will benefit from the experience gained to optimize
the learning curves of new implanting centers. Whereas
step-by-step descriptions of the implantation procedure
have been outlined previously,10 our objective was to focus
specifically on key techniques for avoiding important
complications.METHODS
Patient Population
TAVI was performed on a compassionate basis in 60 patients who were
declined for conventional AVR and not suitable for a transfemoral ap-
proach. Patients were elderly (mean age, 81.1  7.8 years), with multiple
comorbid conditions and a high predicted mortality for AVR (mean Society
of Thoracic Surgeons score, 12.3%  7.8%, logistic EuroScore 35.1% 
20.3%).
Surgical Technique
The TAVI procedure has been previously described.8,10 In our center,
TAVI was performed in a surgical suite, with fluoroscopy—initially using
a C-arm until a hybrid suite was constructed—and transesophageal echo-
cardiography (TEE).11 A 4- to 5-cm anterolateral minithoracotomy inci-
sion was centered over the apex of the left ventricle (LV) in the fifth or
sixth intercostal space, and the pericardium was opened. Apical sutures
were inserted to secure the access site. By needle puncture and standardery c July 2010
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
LV ¼ left ventricle (ventricular)
TAVI ¼ transapical aortic valve implantation
TEE ¼ transesophageal echocardiography
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the aortic valve crossed with a 0.035-inch Amplatz Extra Stiff wire (Bos-
ton Scientific Corp, Natick, Mass). A 100-cm pigtail catheter was intro-
duced via the femoral artery. Systemic heparin was administered to
achieve an activated clotting time of more than 300 seconds. Balloon aortic
valvuloplasty was performed through a 14F sheath with a 20-mm 3 5-cm
(or 3-cm) noncompliant, high-pressure Z-MED balloon (NuMED, Inc,
Hopkinton, NY) during rapid ventricular pacing with temporary epicardial
wires.12 The Edwards SAPIEN transcatheter valve (Edwards LifeSciences,
LLC, Irvine, Calif) is constructed of a bovine pericardial trileaflet valve
within a stainless steel stent and is available in 23- and 26-mm diameter
sizes. The valve was crimped on the delivery balloon, introduced via
a 33F, or more recently a 26F, sheath, and, once in position, balloon-de-
ployed during rapid pacing. Valve function and position were assessed
by TEE and completion aortography. The LV apical sutures were tied to
secure hemostasis. The incision was closed in layers and a chest tube
was inserted.
Analysis of Outcomes
Preoperative characteristics and short-term complications were recorded
prospectively in an institutional transcatheter valve database; additional de-
tails regarding complications were extracted by retrospective chart review.
Ethics approval for this research was granted with waiver of individual con-
sent. Continuous variables were reported as means standard deviation and
discrete variables as number (percent) unless otherwise specified.
RESULTS
Technical success was achieved in 59 (98.3%) patients.
One valve was malpositioned too far toward the ventricle,
and we successfully deployed a second transcatheter valve
slightly cephalad inside the first. Overall 30-day mortality
was 18.3% (11 deaths), including 1 patient (from among
our first 15 cases) who died intraoperatively, likely of left
main occlusion by a heavily calcified native cusp. In-hospi-
tal 30-day mortality was 33.3% in the initial 15 patients,
decreasing to 13.3% in the final 45 patients.
Short-term complications during the postoperative course
were often related to patient comorbid conditions. Intraoper-
ative bleeding occurred in 5 (8.3%) patients, with 3 (5.0%)
cases of LV apical hemorrhage extending through friable LV
free wall tissue necessitating femoral–femoral bypass,
sternotomy without bypass, or extensive off-pump repair
with pledget-supported sutures. Three patients had postoper-
ative bleeding complications, including gastrointestinal and
thoracic wall variceal bleeding. Other complications
included multiple microembolic strokes in 2 (3.3%)
patients: 1 patient with concomitant hypoxic–ischemic
encephalopathy did not awaken postoperatively, and 1
patient had left arm hemiparesis. There was 1 case eachThe Journal of Thoracic and Ca(1.7%) of ischemic bowel, ischemic leg, and multiorgan
dysfunction, and there were 2 cases each (3.3%) of wound
infection and fatal pulmonary embolism. Incident atrioven-
tricular node block necessitating a permanent pacemaker
occurred in 3 (5.0%) patients, including the 1 patient with
device malposition. One patient had late (day 55) ventricular
migration of the valve, and AVR for significant transvalvu-
lar and paravalvular regurgitation 119 days after implanta-
tion was complicated by a fatal postoperative stroke.
Four (6.6%) cases of LV apical pseudoaneurysm at the
access site were identified. One frail patient had apical
hemorrhage intraoperatively and died while awaiting repair;
another required immediate anticoagulation for recurrent
vascular graft thromboses, putatively facilitating oozing
from friable apical myocardium, and underwent repair 7
months later. Conservative management and observation
was carried out for the other 2 pseudoaneurysms, both of
which were associated with deep wound infections, and 1
thrombosed spontaneously.
DISCUSSION
The adoption of new technology for a high-risk
population can be extremely challenging, and patient
selection is key. Unfortunately, predictive scores for AVR
often underestimate risk because they are derived from
surgical candidates and do not consider frailty, prolonged
preoperative hospitalization, immobility, extreme decondi-
tioning, porcelain aorta, liver failure, incomplete coronary
revascularization, or other uncorrected valvular disease.
These factors likely explain the discrepancy between the
observed (17.6%) and predicted mortality (Society of
Thoracic Surgeons score for standard AVR, 12.4% 
7.5%; logistic EuroSCORE 35%  20%). The Leipzig
group has reported results similar to ours, with 92%
1-month survival among their first 50 patients, although
this includes 16 (32%) on-pump implants; we did not
perform any of our implants with pump support, and there
may be other differences between patient populations.13
Precisely because of the excessive risks associated with
these patients’ fixed preoperative characteristics, we believe
that procedural technique is vitally important as one
potentially modifiable factor. Lessons learned from our
experience—as detailed in the following discussion and
illustrations and summarized in Table 1—may assist others
to identify and avoid pitfalls during TAVI and reduce
adverse outcomes.
Room and Setup
A suitable room must be large enough to accommodate all
personnel, equipment, and a sterile back table. Sufficient
slack on the ventilator and intravenous tubing will permit
easier patient repositioning on the floating top, radiolucent
table; and a hybrid operating room with a ceiling-mounted
image intensifier and multiple monitors is preferable tordiovascular Surgery c Volume 140, Number 1 197
TABLE 1. Complications and pitfalls during transcapical aortic valve implantation, with frequency of occurrence and methods to avoid and
manage them
Complication/pitfall Frequency, n (%) Avoidance maneuver and management
Suboptimal intercostal space
(difficulty placing apical sutures and
directing sheaths)
—  Widely drape patient
 Elevate left chest with roll under patient
 Localize apex on surface with hemostat by fluoroscopy
 Confirm selection of intercostal space over apex
visually
 Select lower intercostal space of two otherwise equal
spaces
Poor visibility of LV apex (difficulty
placing apical sutures)
—  Select nearest intercostal space (see above)
 Enlarge incision
 Excise excess pericardial adipose tissue
 Suspend pericardial cut edges
LV apical hemorrhage 3 (5.0%)  Avoid epicardial fat and friable tissue
 Access true LV apex, not free wall, if possible
 Ensure deep (full-thickness, if possible) myocardial
bites with control sutures: use large needles
 Use pledgets to buttress control sutures
 Circumscribe apex widely with control sutures (larger
area than largest sheath to be used)
 Center needle puncture within control sutures
 Avoid excessive movement/angulation of sheaths
 Reinforce apex with extra pledget-supported sutures as
required
 Do not incorporate pericardium into the closure to
avoid obscuring bleeding
 Use cardiopulmonary bypass to repair severe bleeding
(consider rapid ventricular pacing)
Hemorrhage 5 (8.3%)  Ensure hemostasis of chest wall, including chest tube
sites
 Place epicardial pacing sutures where easily visible
 Avoid LV apical hemorrhage (see above)
LV apical pseudoaneurysm 4 (6.6%)  Maintain sterile technique
 Avoid LV apical hemorrhage (see above)
 Avoid early anticoagulation if possible
 Manage wound infections and hypertension
aggressively
 Surveil and, if possible, repair pseudoaneurysms
Ineffective rapid ventricular pacing —  Place epicardial pacing wires in visible myocardium
 Secure pacing wires (clip ends together, and tape pacing
wires to drapes)
 Test pacing and adjust settings to minimize pulsatile
flow
 Consider transvenous pacing as needed
 Ensure clear, two-way communication with operator
Arrhythmia after rapid ventricular pacing 1 (1.7%)  Place and connect defibrillator pads for all cases
 Limit pacing to minimum required
Balloon slippage during valvuloplasty —  Use 5-cm length balloon
 Ensure sheath not interfering with balloon (visualize
sheath by filling with contrast and pull back as needed)
 Only inflate balloon during effective rapid ventricular
pacing (and deflate before cessation of pacing)
(Continued)
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TABLE 1. Continued
Complication/pitfall Frequency, n (%) Avoidance maneuver and management
Valve malpositioning 1 (1.7%)  Do not rush positioning
 Identify aortic annulus, cusps, and sinuses using TEE,
fluoroscopy  contrast, and pigtail catheter position
 Ensure coaxial alignment
 Perform balloon valvuloplasty first (easier to cross
calcified valve and adjust delivery device)
 Rapid ventricular pace if needed during positioning and
to avoid balloon slippage (see above)
 Consider valve-in-valve implant if malpositioned
Coronary obstruction by native cusp 1 (1.7%)  Assess degree of cuspal calcifcation by TEE, especially
if eccentric, severe, and left cuspal
 Locate coronary ostia with aortography
 Assess degree of coronary obstruction during balloon
valvuloplasty
 Possibly consider placing coronary guidewire in ostium
if high risk for obstruction
 May require cardiopulmonary bypass to stabilize
Valve embolization 0  Accurately size the annulus
 Oversize valve slightly, especially in absence of severe
calcification
 Ensure correct valve positioning (see above)
Valve misorientation (upside-down) 0  Double check orientation ex vivo (green suture) and in
vivo (radiodense cranial half) before deployment
Excessive postoperative pain
(respiratory compromise)
—  Avoid rib retraction; use soft tissue retractor
 Avoid unnecessarily large thoracotomy incision
 Infiltrate incision with local anesthetic agent  rib
blocks
 Use small chest tube
LV, Left ventricular; TEE, transesophageal echocardiography.
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Sportable C-arm fluoroscopy with reduced image quality
(Figure 1). A primed bypass circuit and instuments for
peripheral and central cannulation must be readily available.
Double-lumen endotracheal intubation was unnecessary.
The patient was widely draped and positioned supine with
slight elevation of the left hemithorax. Electrocardiographic
leads and defibrillator pads were placed out of the line of
fluoroscopic sight; defibrillation was required after rapid
pacing in 1 case.
Incision
Palpitation of the apex impulse for marking the optimal
incision was often inaccurate in large patients with barrel
chests. We now locate the apex fluoroscopically with
a hemostat on the skin and commence with a small incision
over a rib; this provided two intercostal spaces for consid-
eration, with visual confirmation of proximity to the apex
as the final arbitrator. Of two equally suitable intercostal
spaces, the more inferior one generally allowed easier
cranial angulation of the sheaths toward the aortic valve.The Journal of Thoracic and CaA soft tissue retractor (such as a radiolucent medium
Alexis retractor [Applied Medical Resources Corp, Rancho
Santa Margarita, Calif]) does not spread the ribs, thus
minimizing postoperative pain, which is particularly
important for patients with severe respiratory disease. Local
bupivicaine and a small chest tube further reduce postoper-
ative pain. Pericostal sutures are unnecessary.
Excess extrapericardial fat may be excised. Suspending
the cut pericardial edges with heavy sutures often draws
the apex closer for easier access.
LVApical Access
Hemostatic control of the LV apex is the most critical and
difficult step in TAVI owing to the large sheath and thin,
friable tissue in this patient group. When placing apical
control sutures, avoid epicardial fat, which provides no
additional strength, and take deep bites in the myocardium,
preferably full-thickness bites (Figure 2, A). The true apex is
preferable to the free wall for minimizing myocardial tearing
(owing to lower tension from greater convexity, perrdiovascular Surgery c Volume 140, Number 1 199
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left anterior descending or diagonal coronary artery necessi-
tated choosing a slightly more lateral site.
We used 3-0 polypropylene sutures on a big MH (medium
half [circle]) needle with large (1 3 2 cm) felt pledgets to
make 2 perpendicular horizontal mattress sutures to control
the LV apex and snared them through tensioning tourniquets.
The area bounded by these apical sutures should be approxi-
mately 1.5 cm in diameter and larger than the largest delivery
sheath (currently 26F, although we also previously used 33F
sheaths). Other methods, such as a purse-string technique,
havealso beenused by other groups,14 butmay require a larger
skin incision and more rib spreading to place the sutures.
Next, it is important to make the needle puncture precisely
centrally within the sutures (Figure 2, B). This reduces the
likelihood of tearing the enlarging myocardial defect beyond
the control sutures as larger sheaths are introduced stepwise.
Apical bleeding remains the Achilles’ heel of the procedure.
Bleeding usually can be contained with additional wide pled-
get-supported sutures, being sure to avoid torquing the needles
when passing them through the beating heart. Sternotomy or
on-pump repair may rarely be required to repair extensive tear-
ing and bleeding, and rapid pacing or other maneuvers to re-
duce cardiac motion may also be considered. Do not
incorporate the pericardial edges into the closure to stop bleed-
ing, because this obscures the source of bleeding, with the ex-
ception being reoperations with dense pericardial adhesions.
There may be value in additional apical sutures to also prevent
pseudoaneurysm formation, especially if early postoperative
anticoagulation is necessary.Valvuloplasty
Two temporary epicardial ventricular pacing wires should
be placed where bleeding would be easy to identify, inasmuch
as removal occasionally caused bleeding and in 1 case local
tamponade. The wires are clipped together with a surgical
clip (Figure 2, B) and taped to the drapes to prevent accidentalFIGURE 1. Comparison of high-quality fluoroscopic images of the transcathe
C-arm fluoroscopy (B). The ascending aorta is at the top left corner, and the lef
200 The Journal of Thoracic and Cardiovascular Surgdislodgment. We first tested pacing (1-V output) at a rate just
greater than intrinsic, then at 160 to 200 beats/min, with 20-V
output. If 2:1 block occurs with rapid pacing, the pacing rate is
reduced. The duration of rapid ventricular pacing should be
minimized, particularly in patients with poor LV function or
significant coronary artery disease. Rapid pacing should not
be reinstituted before full hemodynamic recovery. Transve-
nous pacing was rarely required.
Preimplant aortic valvuloplasty (Figure 3) not only makes
deployment easier but also facilitates passing the device
across the native valve and enlarges the orifice to permit
flow during implant positioning. Furthermore, it may help
to assess the potential for coronary ostial obstruction owing
to heavily calcified native cusps, and it is therapeutic in and
of itself for relieving aortic stenosis, albeit temporarily, if
TAVI must be aborted.
Balloon slippage during valvuloplasty, with the need for
repeat dilation, has been largely eliminated with the
antegrade approach and a longer (5-cm) balloon; a 3-cm
balloon is used in patients with prior mitral valve
replacement. The radiolucent 14F sheath can be visualized
if filled with contrast and should be pulled back to avoid
interfering with balloon inflation.Valve Sizing, Positioning, and Deployment
Accurate sizing of the aortic annulus is most reliably
performed with intraoperative TEE, by measuring
between the aortic cusp hinge points in a long-axis view
(Figure 4). Generally speaking, computed tomography
gives a larger annular measurement than TEE, and trans-
thoracic echocardiography measures smaller. A 26-mm
valve is selected for a 22- to 25-mm annulus but may be
used in a 26-mm annulus if significantly calcified;
a 23-mm valve is used for a 17- to 21-mm annulus.
Correct orientation of the valve on the delivery system
must be checked: the green suture is oriented to the inflow
(ventricular) side, and the distal (cephalad) half of theter valve obtained from hybrid room image intensifier (A) versus standard
t ventricular apex is beyond the bottom right corner.
ery c July 2010
FIGURE 2. Technique for hemostatic control of the left ventricular apex. A, Two perpendicular, pledget-supported sutures are placed at the apex (X) to avoid
epicardial fat and vessels; the suture (highlighted) is passed full-thickness through myocardium and then snared with a tensioning tourniquet. B, A needle is
passed through the apex at the central point bounded by the pledget-supported sutures. Temporary ventricular pacing wires are also shown.
Wong et al Evolving Technology/Basic Sciencecrimped valve appears slightly more radiodense by
fluoroscopy (Figure 1) before deployment. By confirming
the orientation with two operators, we have never had any
valves implanted upside-down.
The valve is positioned such that 40% to 50% of the stent
lies on the ventricular side of the calcified valve/annulus be-
fore deployment, and the distal edge of the deployed valve
sits just cephalad to the free edge of the aortic cusps (Fig-
ures 1 and 5). Although we are usually more concerned
about the distal end, placement too far toward the ventricle
may also be problematic, because mitral valve perforation15
or valve embolization may occur with extreme positioning.FIGURE 3. After the stenotic native aortic valve is crossed with a wire (top
inset), balloon aortic valvuloplasty is performed during rapid ventricular
pacing. Dilute contrast solution permits visualization of the balloon under
fluoroscopy (bottom inset).
The Journal of Thoracic and CaObtaining proper coaxial alignment of the valve and aorta
is easier with the transapical than retrograde transfemoral
approach, particularly when there is any amount of horizon-
tal angulation of the aortic root. This is best ensured by
keeping the image intensifier perpendicular to the annular
plane, although usually a straight anteroposterior angle
will suffice. Beware of subtle axial misalignment of the
crimped valve that becomes magnified after deployment.
Where there is little to no aortic calcification, the annulus
can be located by TEE (Figure 5, top inset), root aortography
with hand injections (Figure 5, bottom inset), and by
positioning the radiopaque pigtail catheter to mark the lowest
point of the cusps (Figure 1, B; the pigtail must pulled back
before deployment to avoid entrapment with the transcatheter
valve). The valve rarely needs to be deployed hurriedly; it isFIGURE 4. The aortic annulus is measured between hinge points to size
the transcatheter valve, and transesophageal echocardiography is the most
accurate means of measurement.
rdiovascular Surgery c Volume 140, Number 1 201
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FIGURE 5. The transcatheter valve is positioned with transesophageal
echocardiographic (top inset) and fluoroscopic guidance (bottom inset),
with fine positioning adjustments informed by hand injections of contrast
through a pigtail catheter deep in the aortic root. The valve is positioned
so that 40% to 50% of the stent lies below the annulus (arrow) and so
that the valve extends just cranial to the native cusp edges.
Evolving Technology/Basic Science Wong et al
E
T
/B
Stherefore prudent to position the valve meticulously. In rare
cases, temporary rapid ventricular pacing will be needed to re-
duce excessive cardiac and annular motion during
positioning.
Postoperative Management
Owing to the risk of falls and hemorrhagic complications
early in our series, postoperative warfarin was abandoned in
favor of aspirin 81 mg plus clopidogrel 75 mg once daily.
Avoiding nephrotoxic drugs and limiting intravenous con-
trast are important, because renal insufficiency was com-
mon. Good hypertensive control may reduce the risk
bleeding and apical pseudoaneurysms.202 The Journal of Thoracic and Cardiovascular SurgCONCLUSION
TAVI is a complementary technique to the transfemoral
approach and offers several potential advantages, including
greater stability during device delivery, avoidance of periph-
eral vascular access concerns, and reduced aortic arch instru-
mentation. Nevertheless, important technical challenges and
the steep learning curve have implications for training and
maintenance of competence.
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